Experience of Teraligen usage in pediatric psychiatry

Close metadata

Recommended articles:

Clinical and psychometric characteristics of cognitive and negative disorders in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):64-71

Management of patients with insomnia and polymorbidity. A draft of the clinical guidelines. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):39-52

The intensity of neuropathic pain and the severity of insomnia in diabetic polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):87-92

Sleep disorders in patients with medication-overuse headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):93-98

Sleep disorders during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):99-104

Sleep disorders and oncological diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):125-131

Antidepressants in psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):126-132

Tooth decay and autism spectrum disorders in children: is there a connection?. Stomatology. 2024;(2):71-76

Our experience in the treatment of congenital nasal median heterotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32

Comorbid disorders and risk factors for neiropathic pain in distal diabetic polyneuropathy. Russian Journal of Pain. 2024;(2):41-48

The data of studies on the use of Teraligen in various fields of clinical medicine — neurology, dermatology, gastroenterology, anesthesiology and psychiatry are presented. According to studies conducted in psychiatry, Teraligen is a drug for the balanced treatment of anxiety-phobic, behavioral and sleep disorders in children, both within neurotic conditions and in the structure of autistic and schizophrenic spectrum disorders. Based on 100 case histories of children aged 3 to 16 years, the experience of using Teraligen as part of mono- and combination therapy at a dosage of 1.25 mg to 50 mg/day in the treatment of autism spectrum disorders (n=31), psychotic disorders (n=18), schizotypal disorders (n=41), behavioral and emotional disorders on residual organic soil (n=10). A good clinical effect of Teraligen has been shown in anxiety-phobic, affective, somatovegetative disorders and sleep disorders in all identified nosologies. Good tolerability of Teraligen, the possibility of its use as part of complex therapy and the almost complete absence of adverse events, indicating the softness and balance of the drug were noted.

Keywords:

childhood

Teraligen

neurotic disorders

autism spectrum disorders (ASD)

schizophrenia

schizotypal disorder

behavioral disorders

sleep disorders

Authors:

Goryunov A.V.

Mental Health Research Center

SPIN RSCI: 6932-3880
Scopus AuthorID: 35773220700
ResearcherID: B-9476-2017
ORCID: 0000-0002-2851-8843

Sergeeva O.E.

Mental Health Research Center

Received:

11.04.2022

Accepted:

11.04.2022

List of references:

Courvoisier S, Ducrot R, Fournel J, et al. Proprietes pharmacologiques generales d’un nouveau derive de la pheniothiazine neuroleptique puissant a action neurovegetativ discrete, le chlorhydrate de (methyl-2 dimethylamino-3 propyl-1)-10 phenothiazine (6.549 RP). Arch Int Pharmacodyn Ther. 1958;115(1-2):90-113.
Hudson AL. A new drug for control of itching — Trimeprazine [10-(3-Dimethylamino-2-Methylpropyl)-Phenothiazine]. Can Med Assoc J. 1959;80(2):125.
Ibragimov DF. Alymemazine in medical practice. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(9):76-78. (In Russ.).
Pushkarev DF. Alimemazine in psychiatric practice and general medicine (literature review). Psikhicheskie Rasstroistva v Obshchei Meditsine. 2013;1:56-61. (In Russ.). https://con-med.ru/magazines/psikhicheskie_rasstroystva_v_obshchey_meditsine-01-2013
Bekker RA, Bykov YV. Alimemazine: application overview. Psychiatry and psychopharmacotherapy = Psikhiatriia i Psikhofarmakoterapiia. 2016;18(6):10-20. (In Russ.). https://psychiatr.ru/download/2903?view=1&name=Psi+6+2016%28Low%29.pdf
Medvedev VE. Alimemazine in psychiatry and psychosomatic. Psychiatry and Psychopharmacotherapy = Psikhiatriia i Psikhofarmakoterapiia. 2018;20(3-4):26-33. (In Russ.).
Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268(3):1403-1410.
Glusa E, Pertz HH. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT2B receptors. Br J Pharmacol. 2000;130(3):692-698. https://doi.org/10.1038/sj.bjp.0703341
Savelev DV, Reznik AM, Chernov AS, et al. Alimemazine in treatment of agitation in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(6-2):68-76. (In Russ.). https://doi.org/10.17116/jnevro202012006268
Edin AS. To the question of the use of alimamazine (Teraligen) in patients with atopic dermatitis in combination with anxiety-depressive disorder. Consilium Medicum. 2018;20(2):145-150. (In Russ.). https://doi.org/10.26442/2075-1753_2018.2.145-150
Pribytkov AA, Orlova EA. Psikhosomaticheskie rasstroistva s proiavleniiami v vide urtikarnoi sypi. Psychiatry and Psychopharmacotherapy. 2014;2:47-53. (In Russ.).
Antao B, Ooi K, Ade-Ajayi N, Stevens Spitz L. Effectiveness of alimemazine in controlling retching after Nissen fundoplication. Journal of Pediatric Surgery. 2005;40:1737-1740.
Demyanov IA, Boiko EO, Zaitseva OG, et al. The efficacy of alimemazine (solution for intramuscular injection) in complex with antidepressants in the treatment of anxiety and depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(8):32-37. (In Russ.). https://doi.org/10.17116/jnevro201911908132
Morozova MA, Alekseev AA, Rupchev GE. Alimemazine: a convenient therapeutic tool for solving some complex problems in the treatment of functional psychotic disorders (clinical cases). Modern Therapy of Mental Disorders. 2017;2:40-43. (In Russ.).
Poluektov MG. Narusheniia sna v detskom vozraste: prichiny i sovremennaia terapiia. Effektivnaia Farmakoterapiia. 2012;1:32-39. (In Russ.).
Gurtler J, Goralsky G. Testing of theralene on 70 mentally-defective and unstable children and children with character disorders and mental retardation, in an I.M.P. medical unit. Rev Neuropshychiat Infant. 1961;9:284-287.
Simonoff EA, Stores G. Controlled trial of trimeprazine tart rate for night waking. Arch Disease Childhood. 1987;62(3):253-257. https://doi.org/10.1136/adc.62.3.253
Richman NA. Double blind trial of drug treatment in young children with waking problems. J Child Psychol Psychiat. 1985;26(4):591-598. https://doi.org/10.1111/j.1469-7610.1985.tb01643.x
Oftsti E. Alimemazine (Vallergan) an alternative to traditional hypnotic drugs. Tidsskr Nor Laegeforen. 1975;9(31):1796-1797.
Goryunova AV, Goryunov AV. Classification metamorphoses of autism in child psychiatry. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021;121(11 vyp 2):5-11. (In Russ.). https://doi.org/10.17116/jnevro20211211125
Aleshina NV. The use of the drug «Teralidzhen» in the structure of pharmacotherapy of early childhood autism (procedural and organic). Mental health. 2014;12:2(93):70-72. (In Russ.).
Aleshina NV, Filippova NV, Barylnik YuB. Teraligen in the complex therapy of organic and procedural early childhood autism. International Research Journal. 2014;2-3(21):89-90. (In Russ.).
Aleshina NV. Therapy of autistic disorders with Teraligen (Alimemazine) in pediatric practice on an outpatient basis. Psychiatry and psychopharmacotherapy = Psikhiatriia i Psikhofarmakoterapiia. 2018;20(1):23-26. (In Russ.).
Simashkova NV. Effective pharmacotherapy and rehabilitation of patients with autism spectrum disorders. Neurology and Psychiatry. 2011;3:14-22. (In Russ.).
Zueva GA. Opyt primeneniia alimemazina tartrata dlia korrektsii narushenii sna u podrostkov s golovnoi bol’iu napriazheniia. V kn.: Aktual’nye voprosy reabilitatsii v nevrologii i psikhiatrii. Materialy nauchno-prakticheskoi konferentsii. Tver’: GBOU VPO Tverskaia GMA Minzdrava Rossii; 2014;16-18. (In Russ.).
Chervin RD, Arcbhold KH, Panahi P, et al. Sleep problems seldom addressed at two general pediatrics clinics. Pediatrics. 2001;107(6)1375-1380. https://doi.org/10.1542/peds.107.6.1375
Malinina EV, Chizhova TN, Zabozlaeva IV, et al. Study of the efficacy and tolerability of alimemazine in children with mixed disorder of emotions and behavior. Child neurology and psychiatry. 2015;106-107(5-6):67-70. (In Russ.).
Mazaeva NA, Golovina AG. Alimemazine in outpatient therapy of non-psychotic mental disorders in adolescents. Psychiatry. 2015;1(65):11-16. (In Russ.).
Balakireva EE. Eating disorders in children and adolescents. Psychiatry. 2013;4:16-21. (In Russ.).
Goryunov AV. Using Lurasidone in the treatment of mental illness in childhood. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(11 issue 2):77-85. (In Russ.). https://doi.org/10.17116/jnevro202112111277
Sychev DA, Otdelenov VA. Interdrug interactions in the practice of an internist: a clinical pharmacologist’s perspective. Reference Book of the Polyclinic doctor. 2014;12:18-21. (In Russ.).
Kirilochev OO, Umerova AR, Dorfman IP, et al. The drug-drug interactions in a psychiatric hospital. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(5):26-30. (In Russ.). https://doi.org/10.17116/jnevro20171175126-30

Close metadata